LIVE WEBINAR: Tuesday, January 7, 2025, 5:00 PM – 6:00 PM ET

Oncology Q&A: Addressing Common Questions Posed by Patients with Metastatic Triple-Negative Breast Cancer

A CME/MOC-Accredited Webinar Developed in Partnership with the Triple Negative Breast Cancer Foundation
Triple Negative Breast Cancer Foundation

Register Now

Register for this complimentary event with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Tuesday, January 7th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Faculty
Lisa A Carey, MD, ScM, FASCO
L Richardson and Marilyn Jacobs Preyer
Distinguished Professor for Breast Cancer Research
Deputy Director for Clinical Sciences
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, North Carolina

Rita Nanda, MD
Director, Breast Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by an educational grant from Gilead Sciences Inc.

Tuesday, January 7, 2025
5:00 PM – 6:00 PM eastern time
Live CME/MOC-accredited webinar

A detailed agenda will be made available in the coming weeks.

Topics to Be Discussed

  • Biology of Metastatic Triple-Negative Breast Cancer (mTNBC)
  • Treatment Options for mTNBC
  • Tolerability of Common Therapies for mTNBC

Target Audience
This activity is intended for medical oncologists, breast surgeons, hematologists, hematology-oncology fellows, radiation oncologists and other healthcare professionals involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the importance of shared decision-making, and employ novel approaches and resources to improve counseling and treatment discussions with patients with metastatic triple-negative breast cancer (mTNBC) and their care teams.
  • Reflect on the viewpoints of disease-specific clinical investigators regarding best-practice management approaches for patients with mTNBC, and use this information to discuss appropriate therapeutic recommendations.
  • Evaluate published research findings, patient preferences and clinical factors such as age, performance status, prior therapeutic exposure and PD-L1/BRCA/HER2-low status in the selection and sequencing of therapy for mTNBC.
  • Appreciate available clinical trial data with approved antibody-drug conjugates for mTNBC in order to optimally incorporate these agents into treatment algorithms.
  • Recognize the spectrum, frequency and severity of treatment-emergent adverse events associated with agents commonly used in the management of mTNBC, and develop strategies to monitor for, prevent and manage these complications.
  • Describe the challenges encountered by patients with mTNBC, and enact efforts within current practice to overcome these barriers.

CE Credit
CME, ABIM MOC and ABS credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY Dr Carey has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Exact Sciences Corporation, GE Healthcare, Gilead Sciences Inc, Guardant Health, Merck, Moderna, Novartis, OBI Pharma Inc, Pfizer Inc, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Corcept Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Merck, Novartis, OBI Pharma Inc, Pfizer Inc, Relay Therapeutics, Seagen Inc, Sun Pharmaceutical Industries Ltd, Taiho Oncology Inc. 

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporter
This activity is supported by an educational grant from Gilead Sciences Inc.